Do you want to read an article? Please log in or register.
Targeting Treatable Traits in Severe Asthma: A Randomised Controlled Trial
Asthma
RECOMMENDED
Related content
RECOMMENDED
Asthma
Randomised controlled trials in severe asthma: selection by phenotype or stereotype
Eur Respir J.
Brown T, Jones T, Gove K, Barber C, Elliott S, Chauhan A, Howarth P; Wessex Severe Asthma Cohort (WSAC) team; Members of the Wessex Severe Asthma Cohort (WSAC) team
doi: 10.1183/13993003.
Asthma
Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial
Lancet Respir Med.
Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A
doi: 10.1016/
Asthma
Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials
Lancet Respir Med.
Brightling CE, Gaga M, Inoue H, Li J, Maspero J, Wenzel S, Maitra S, Lawrence D, Brockhaus F, Lehmann T, Brindicci C, Knorr B, Bleecker ER
doi: 10.1016/S2213-2600(20)30412-4.
Asthma
Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials
Lancet Respir Med.
Panettieri R, Sjöbring U,
Péterffy AM, Wessman P, Bowen K, Piper E, Colice G, Brightling Ch
doi: 10.1016/
Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial
Read the comment: Effectiveness trials in asthma: time to SaLSA? >>>
doi: 10.1016/
COMMENTED
Asthma
Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial
★ 3
Recommended and commented by
Dr Martin Frey, Faculty Member
Lancet Respir Med.
Heaney LG, Busby J, Hanratty CE, Djukanovic R, Woodcock A, Walker SM, Hardman TC, Arron JR, Choy DF, Bradding P, Brightling CE, Chaudhuri R, Cowan DC, Mansur AH, Fowler SJ, Niven RM, Howarth PH, Lordan JL, Menzies-Gow A, Harrison TW, Robinson DS, Holweg CTJ, Matthews JG, Pavord ID, investigators for the MRC Refractory Asthma Stratification Programme.
doi: 10.1016/S2213-2600(20)30397-0.
Asthma
Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet Respir Med.
Ferguson GT, FitzGerald JM, Bleecker ER, Laviolette M, Bernstein D, LaForce C, Mansfield L, Barker P, Wu Y, Jison M, Goldman M; BISE Study Investigators
doi: 10.1016/
Asthma
A pilot randomized controlled trial on the impact of text messaging check-ins and a web-based asthma action plan versus a written action plan on asthma exacerbations
J Asthma.
Poureslami I, Shum J, Lester RT, Tavakoli H, Dorscheid DR, FitzGerald JM
RECOMMENDED
Asthma
Unmet Needs in Severe Asthma Subtyping and Precision Medicine Trials: Bridging Clinical and Patient Perspectives
Am J Respir Crit Care Med.
Siddiqui S, Denlinger LC, Fowler SJ, Akuthota P, Shaw DE, Heaney LG, Brown L, Castro M, Winders TA, Kraft M, Wagers S, Peters MC, Pavord ID, Walker S, Jarjour NN
doi: 10.1164/rccm.